Company intelligence / Profile preview

F-Prime Capital

Cambridge, Massachusetts, United Statesbiohealthinnovation.org ↗

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Fidelity Biosciences was the venture capital arm of Fidelity Investments focused on private investments in biopharmaceuticals, medical technology, healthcare services and health IT. In 2015 it merged with Devonshire Investors and rebranded as F‑Prime Capital. The firm has invested in over 290 companies globally—including major biotech names like Moderna and Affinia Therapeutics—across all stages of company development. It does not develop drugs itself but backs innovative life sciences companies at various clinical and commercial stages

Industry: Investors

Partnerships

Adaptimmune (UK)Dimension Therapeutics (US)Innovent Biologics (China)Forum Pharmaceuticals

Beyond the preview

Go deeper on F-Prime Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F-Prime Capital.

Explore the full profile